Clinical trials: Multidrug-Resistant Bacterial Infections
Gram-Negative Bacterial Infections, Gram-negative Bacteremia
Comparison of Solid Organ Transplant
Solid organ transplant (SOT) recipients have increased incidence of infections with MDRO pathogens. This difference leads to a disparity in antibiograms between SOT recipients and other hospitalized patients.
- Conditions
- Gram-Negative Bacterial Infections, Gram-negative Bacteremia, Multidrug-Resistant Organism, Hospital-acquired Pneumonia
- Trial name
- NCT04055922
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Methodist Health System
Viral Infection, Bacterial Infections
Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO
The fast increase of Multidrug-resistant microorganisms (MDRO) due to the high amount of antimicrobials being poorly used may be limited by better regulating antimicrobial usage globally.
- Conditions
- Viral Infection, Bacterial Infections, Multi-antibiotic Resistance, Respiratory Tract Infections
- Trial name
- CRONUS (NCT05897801)
- Testing
- MeMed BV®
- Where
- 3 sites in Greece
- Volunteers
- 230 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Pneumonia - Bacterial, Urinary Tract Infection Bacterial
Clinical Impact of a Machine Learning Decision Support System for Empirical Antibiotic Therapy
The goal of this quasi-experimental study is to analyze if a Machine Learning Clinical Decision Support System can improve the empirical antibiotic treatment in patients with pneumonia, urinary tract infection and / or sepsis.
- Conditions
- Pneumonia - Bacterial, Urinary Tract Infection Bacterial, Bloodstream Infection
- Trial name
- NCT07762378
- Testing
- Machine Learning Decision Support System
- Volunteers
- 486 people
- Sponsor
- Instituto de Investigación Sanitaria Gregorio Marañón
Bacterial Infections, Fungal Infection
Study to Optimize the Use of New Antibiotics
Quasi-experimental intervention multicenter trial of patients treated with new antibiotics (before-after study). The study will be carried out in 14 hospitals of the Andalusian Public Health System with representation from all…
- Trial name
- NEW_SAFE (NCT03941951)
- Testing
- Non-impositive Program for Optimizing the Use of Antimicrobials
- Where
- 14 sites in Spain
- Volunteers
- 900 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Tuberculosis, Multidrug-Resistant
Clinical Evaluation of tNGS for Diagnosis of DR-TB
Current rapid molecular assays for detection of drug-resistant TB from direct clinical samples have important limitations. They are not suited for high-throughput settings; can only be used to detect a limited number of target…
- Trial name
- Seq&Treat (NCT04239326)
- Testing
- targeted Next Generation Sequencing (tNGS)
- Where
- 3 sites in Georgia, India and 1 more
- Volunteers
- 800 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Multidrug Resistant Tuberculosis
NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB
Tuberculosis (TB) has been one of the top 10 causes of death worldwide from a single infectious agent, ranking above HIV/AIDS. Management and eradication of this disease is being hindered by the emergence of multidrug-resistant…
- Trial name
- GRACE-TB (NCT03604848)
- Testing
- WHO-approved MDR-TB regimen, NGS-guided regimen: Regimen A, NGS-guided regimen: Regimen B
- Where
- 12 sites in China
- Volunteers
- 488 people
- Sponsor
- Huashan Hospital
Tuberculosis
Genome Sequencing of Multidrug Resistant Tuberculosis (MDR TB) in Sputum
Drug resistant tuberculosis is a growing problem world wide. The current methods for diagnosis are time consuming and may delay diagnosis and treatment for many weeks.
- Trial name
- MDRTB01 (NCT02245347)
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- St George's Healthcare NHS Trust
HIV Infections, Tuberculosis
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
To determine the demographic, behavioral, clinical, and geographic risk factors associated with the occurrence of multidrug-resistant pulmonary tuberculosis (MDRTB).
- Trial name
- NCT00000796
- Testing
- Cycloserine, Ethionamide, Capreomycin sulfate
- Where
- 21 sites in United States
- Volunteers
- 525 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis (TB)
Cardiometabolic Risk Factors Associated With Multidrug-Resistant Tuberculosis
Background: MDR-TB (Multidrug Resistant tuberculosis) remains a major public health concern, especially in high-burden countries like Nepal.
- Trial name
- NCT07003581
- Where
- Nepal
- Volunteers
- 183 people
- Sponsor
- B.P. Koirala Institute of Health Sciences
Tuberculosis, MDR
FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis
Drug-resistant tuberculosis is becoming a major problem for the whole humanity, and development of new Anti-TB drugs is of great importance.
- Trial name
- FS-1 (NCT02607449)
- Testing
- FS-1
- Where
- 6 sites in Kazakhstan, Kyrgyzstan
- Volunteers
- 344 people
- Sponsor
- Scientific Center for Anti-infectious Drugs, Kazakhstan
MDR-TB, Tuberculosis Multi Drug Resistant Active
Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)
The FAST-MDR trial is an externally-controlled, multicentre trial with one prospective arm, evaluating the non-inferiority of the effectiveness of BPaLM in the interventional arm versus the effectiveness of the long, conventional…
- Conditions
- MDR-TB, Tuberculosis Multi Drug Resistant Active, Antibiotic Resistance, Mycobacterium Tuberculosis
- Trial name
- FAST-MDR (NCT07486024)
- Testing
- Bedaquiline Oral Tablet
- Where
- 5 sites in France
- Volunteers
- 55 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multidrug Resistant Tuberculosis
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
PRACTECAL-PRO is a sub-study of a TB-PRACTECAL clinical trial for multidrug resistant Tuberculosis. It evaluates the effectiveness of TB-PRACTECAL interventions from the patient perspective in terms of their quality of life…
- Trial name
- PRACTECAL-PRO (NCT03942354)
- Testing
- Bedaquiline, Pretomanid, Moxifloxacin
- Where
- 6 sites in Belarus, South Africa and 1 more
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Medecins Sans Frontieres, Netherlands
Tuberculosis, Tuberculosis, Multidrug-Resistant
Tuberculosis in China
Background: In spite of well-researched treatments and therapies, 5 to 10 percent of tuberculosis (TB) patients who have initially successful TB treatments will relapse, usually within a year after completion of therapy.
- Conditions
- Tuberculosis, Tuberculosis, Multidrug-Resistant, Extensively Drug Resistant Tuberculosis
- Trial name
- NCT01071603
- Where
- China
- Volunteers
- 199 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Drug Resistance, Multiple, Bacterial, Cholangiopancreatography, Endoscopic Retrograde
Prevalence of Multidrug Resistant Micro-organism Carriage in Patients Undergoing an ERCP in Four Different Countries
The duodenoscopes currently used for Endoscopic Retrograde Cholangio - and Pancreaticography (ERCP) examinations are reusable and are therefore washed and disinfected after each use.
- Trial name
- PREVENT (NCT05303662)
- Testing
- Multidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabs, MDRO-testing duodenal aspirate, Microbiome through rectal swab
- Where
- 4 sites in United States, India and 2 more
- Volunteers
- 1,244 people
- Sponsor
- Marco J. Bruno
Tuberculosis, Multidrug-Resistant
Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB
Multi-drug-resistant tuberculosis (MDR-TB) affects nearly 600,000 persons each year around the world. This type of tuberculosis is very difficult to treat, and many patients die from it.
- Trial name
- Opti-Q (NCT01918397)
- Testing
- Levofloxacin, Optimized background regimen (OBR)
- Where
- 3 sites in Peru, South Africa
- Volunteers
- 111 people
- Sponsor
- Boston University
Drug-resistant Tuberculosis, HIV Coinfection
Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes.
- Conditions
- Drug-resistant Tuberculosis, HIV Coinfection, Cost-Benefit Analysis
- Trial name
- TSELiOT (NCT05553236)
- Testing
- Targeted next-generation sequencing
- Where
- South Africa
- Volunteers
- 2,500 people
- Sponsor
- University of California, San Francisco
Crohn Disease, Ulcerative Colitis
Safety and Efficacy of Fecal Microbiota Transplantation
The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease…
- Conditions
- Crohn Disease, Ulcerative Colitis, Celiac Disease, Irritable Bowel Syndrome
- Trial name
- NCT04014413
- Testing
- Fecal Microbiota Transplantation
- Where
- Hong Kong
- Volunteers
- 450 people
- Sponsor
- Chinese University of Hong Kong
Pleural Empyema, Tuberculosis (TB)
The Role of Decortication in Complex Empyema Cases: Multidrug Resistance and Tuberculosis at the Forefront
Empyema is a problem that thoracic surgeons deal in everyday practice. The main goal of treatment is evacuating the pus and fibrin deposits in the thoracic cavity for complete lung expansion.
- Conditions
- Pleural Empyema, Tuberculosis (TB), Bacterial Sepsis
- Trial name
- NCT07167823
- Testing
- Decortication
- Where
- Pakistan
- Volunteers
- 350 people
- Sponsor
- University of Health Sciences Lahore
Rifampicin Resistant Tuberculosis, Drug-resistant Tuberculosis
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
The primary aim of this pragmatic trial is to determine the effectiveness of a Whole Genome Sequencing (WGS) Drug Sensitivity Testing (DST) strategy to guide individualised treatment of rifampicin resistant tuberculosis (RR-TB)…
- Conditions
- Rifampicin Resistant Tuberculosis, Drug-resistant Tuberculosis, Multidrug Resistant Tuberculosis, Pulmonary Tuberculoses
- Trial name
- SMARTT (NCT05017324)
- Testing
- WGS DST strategy
- Where
- South Africa
- Volunteers
- 248 people
- Sponsor
- Universiteit Antwerpen
Tuberculosis, MDR
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among…
- Trial name
- PHOENIx MDR-TB (NCT03568383)
- Testing
- Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6)
- Where
- 31 sites in Botswana, Brazil and 11 more
- Volunteers
- 5,832 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)